Lamivudine/nevirapine/zidovudine - Mylan Laboratories

Drug Profile

Lamivudine/nevirapine/zidovudine - Mylan Laboratories

Alternative Names: Lamivudine/zidovudine/nevirapine - Mylan Laboratories; Nevirapine/lamivudine/zidovudine - Mylan Laboratories; Nevirapine/zidovudine/lamivudine - Mylan Laboratories; Zidovudine/lamivudine/nevirapine - Mylan Laboratories; Zidovudine/nevirapine/lamivudine - Mylan Laboratories

Latest Information Update: 24 Jul 2015

Price : $50

At a glance

  • Originator Mylan Laboratories Limited
  • Class 3-ring heterocyclic compounds; Antiretrovirals; Azepines; Azides; Cyclopropanes; Dideoxynucleosides; Nucleosides; Pyridines; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration HIV-1 infections

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top